Ultrafiltration using the Amicon MPS-1 for assessing methadone plasma protein binding

Area of Science:

• Pharmacology
• Analytical Chemistry
• Clinical Chemistry

Background:

• Methadone is a widely used opioid agonist therapy for opioid use disorder.
• Understanding the unbound fraction of methadone is crucial for optimizing therapeutic efficacy and minimizing adverse effects.
• Existing methods for separating protein-bound and protein-free methadone can be complex and time-consuming.

Purpose of the Study:

• To evaluate the efficacy of the Amicon MPS-1 ultrafiltration device for separating protein-free and protein-bound methadone.
• To determine the concentration of free and bound methadone in plasma samples from patients undergoing methadone maintenance therapy.
• To investigate the relationship between free methadone levels, total methadone levels, patient demographics, and methadone dosage.

Main Methods:

• Ultrafiltration using the Amicon MPS-1 device to separate protein-free and protein-bound methadone fractions.
• Extraction of methadone from separated fractions.
• Quantification of methadone concentrations using gas chromatography with nitrogen-phosphorus detection.
• Analysis of 85 patient plasma samples from a methadone maintenance program.

Main Results:

• The Amicon MPS-1 device effectively separated protein-free and protein-bound methadone, with no measurable proteins in the filtrate.
• The ultrafiltration process was independent of methadone concentration and sample volume (up to 40% filtration).
• Patient samples exhibited a sixfold variation in %-free methadone, with slightly higher levels in females (11.9% +/- 3.8%) compared to males (10.1% +/- 3.4%).
• Steady-state free and total methadone levels positively correlated with increasing methadone dose (r=0.521 and r=0.491, respectively).
• Free methadone levels showed a strong correlation with total methadone levels (Pearson r=0.85).

Conclusions:

• The Amicon MPS-1 ultrafiltration system is a reliable and user-friendly method for separating protein-free from protein-bound methadone.
• Significant variability in free methadone levels exists among patients, suggesting potential clinical relevance.
• Further research is warranted to elucidate the clinical applications and implications of monitoring free methadone levels in patients on maintenance therapy.